There shall be no administrative or judicial review of any of the following:
(1) The determination of a unit, with respect to a drug or biological product, pursuant to section 1320f(c)(6) of this title.
(2) The selection of drugs under section 1320f–1(b) of this title, the determination of negotiation-eligible drugs under section 1320f–1(d) of this title, and 1 the determination of qualifying single source drugs under section 1320f–1(e) of this title the 2 application of section 1320f–1(f) of this title,.3
(3) The determination of a maximum fair price under subsection (b) or (f) of section 1320f–3 of this title.
(4) The determination of renegotiation-eligible drugs under section 1320f–3(f)(2) of this title and the selection of renegotiation-eligible drugs under section 1320f–3(f)(3) of this title.
Editorial Notes
Amendments
2022—Par. (2). Pub. L. 117–169, §11002(a)(5), which directed the amendment of subsec. (b)(2) of this section by inserting "the application of section 1320f–1(f) of this title," after "section 1320f–1(e) of this title", was executed by making the insertion in par. (2) to reflect the probable intent of Congress.
1 So in original. The word "and" probably should not appear. 2 So in original. Probably should be preceded by ", and". 3 So in original.Tried the LawStack mobile app?
Join thousands and try LawStack mobile for FREE today.
- Carry the law offline, wherever you go.
- Download CFR, USC, rules, and state law to your mobile device.
